The arranged marriage of cangrelor and bivalirudin

Affiliations

¹ ACTION Study Group, Institut de Cardiologie (AP-HP), Hôpital Pitié-Salpêtrière, University Paris 6, INSERM UMRS 1166, Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.
² ACTION Study Group, Institut de Cardiologie (AP-HP), Hôpital Pitié-Salpêtrière, University Paris 6, INSERM UMRS 1166, Paris, France.

Free article

Editorial

Gilles Montalescot et al. JACC Cardiovasc Interv. 2015 Mar.

Free article

. 2015 Mar;8(3):434-435.

doi: 10.1016/j.jcin.2015.01.004. Epub 2015 Feb 18.

¹ ACTION Study Group, Institut de Cardiologie (AP-HP), Hôpital Pitié-Salpêtrière, University Paris 6, INSERM UMRS 1166, Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.
² ACTION Study Group, Institut de Cardiologie (AP-HP), Hôpital Pitié-Salpêtrière, University Paris 6, INSERM UMRS 1166, Paris, France.

No abstract available

Keywords: P2Y(12) antagonists; anticoagulation; antiplatelet therapy; percutaneous coronary intervention; stent thrombosis.

Comment on

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. White HD, et al. JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703887 Clinical Trial.